INT103886

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2002
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 5
Total Number 5
Disease Relevance 2.16
Pain Relevance 0.71

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Agtr2) transcription factor binding (Agtr2) signal transducer activity (Agtr2)
Anatomy Link Frequency
blood 2
platelet 2
Agtr2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
headache 6 99.98 Very High Very High Very High
aspirin 2 99.98 Very High Very High Very High
cINOD 1 98.48 Very High Very High Very High
ischemia 8 93.08 High High
anesthesia 1 86.36 High High
corticosteroid 1 53.40 Quite High
Disease Link Frequency Relevance Heat
Hypertension 5 98.72 Very High Very High Very High
INFLAMMATION 1 98.28 Very High Very High Very High
Cough 1 97.96 Very High Very High Very High
Focal Segmental Glomerulosclerosis 9 96.16 Very High Very High Very High
Stroke 6 96.12 Very High Very High Very High
Cv Unclassified Under Development 8 93.08 High High
Cv General 4 Under Development 4 85.16 High High
Proteinuria 1 69.72 Quite High
Headache 4 68.24 Quite High
Chronic Renal Failure 1 51.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
[Inhibition of platelet aggregation and angiotensin II-receptor blockade following TIA; the unexpected results of the Prevention Regimen For Effectively Avoiding Second Strokes (PROFESS) trial].
Negative_regulation (Inhibition) of Negative_regulation (blockade) of angiotensin II-receptor in platelet associated with aspirin and stroke
1) Confidence 0.31 Published 2008 Journal Ned Tijdschr Geneeskd Section Title Doc Link 18808078 Disease Relevance 0.72 Pain Relevance 0.26
Losartan, candesartan, valsartan, which are AT1 receptor blockers (ARB); PD123319, an AT2 receptor blocker; enalapril, an ACE inhibitor; or diphenylene iodonium, a NADPH oxidase inhibitor, was given i.v. 10 mins, and beta-NADPH, a NADPH oxidase substrate, was given i.v. 5 mins before reperfusion.
Negative_regulation (inhibitor) of Negative_regulation (blocker) of AT2 receptor
2) Confidence 0.17 Published 2010 Journal J. Physiol. Pharmacol. Section Abstract Doc Link 20436217 Disease Relevance 0.47 Pain Relevance 0.32
Angiotensin II receptor blockers, such as eprosartan, are as effective as ACE inhibitors in reducing blood pressure, but lack the main adverse effect of ACE inhibitors, namely cough.
Negative_regulation (lack) of Negative_regulation (blockers) of Angiotensin II receptor in blood associated with cough
3) Confidence 0.07 Published 2002 Journal Drug Saf Section Abstract Doc Link 12113644 Disease Relevance 0.10 Pain Relevance 0
Non-immunosuppressive therapy (i.e. angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, lipid-lowering drugs, non-steroidal anti-inflammatory drugs) should be applied to almost all patients with primary FSGS.
Negative_regulation (inhibitors) of Negative_regulation (blockers) of angiotensin II receptor associated with inflammation, focal segmental glomerulosclerosis and cinod
4) Confidence 0.03 Published 2003 Journal Nephrol. Dial. Transplant. Section Abstract Doc Link 12817066 Disease Relevance 0.70 Pain Relevance 0.13
The efficacy and tolerability of eplerenone, a selective aldosterone blocker, was assessed when added to existing antihypertensive therapy with an ACE inhibitor or an angiotensin II receptor blocker (ARB).
Negative_regulation (inhibitor) of Negative_regulation (inhibitor) of angiotensin II receptor
5) Confidence 0.02 Published 2002 Journal Hypertension Section Abstract Doc Link 12154100 Disease Relevance 0.17 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox